^
    7ms
    Biocartis and Merck to collaborate on improving patient access to personalized medicine in Middle East and North Africa (MEA) region (Biocartis Press Release)
    "Biocartis...announced an expansion of its collaboration with Merck Serono Middle East and Merck Saudi Ltd...The collaboration aims to improve patient access to RAS biomarker testing in the Middle East and North Africa (MEA) region."
    Licensing / partnership
    |
    Idylla™ KRAS Mutation Test • Idylla™ NRAS-BRAF Mutation Test
    12ms
    PARERE: PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence (clinicaltrials.gov)
    P2; Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600
    |
    Idylla™ NRAS-BRAF Mutation Test
    |
    Avastin (bevacizumab) • Vectibix (panitumumab) • Stivarga (regorafenib) • oxaliplatin • irinotecan
    over1year
    RAS/ BRAF molecular profile in metastatic versus non-metastatic colorectal cancer (ESMO-GI 2023)
    Our results highlighted a difference in the molecular profile of KRAS, NRAS,and BRAF mutations' distribution between metastatic colorectal cancer and non-metastatic ones: NRAS and BRAF mutations were associated with metastasis advent; moreover, the G13D mutation of KRAS was correlated to a better prognosis than mutations in codon 12 of KRAS: G12A and G12S alleles gave the worst prognosis.
    Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • BRAF mutation • NRAS mutation • KRAS G12D • KRAS G12V • RAS mutation • KRAS G12A • KRAS G12 • KRAS G12S • KRAS G13 • NRAS G12D • NRAS G13 • NRAS G12S
    |
    Idylla™ KRAS Mutation Test • Idylla™ NRAS-BRAF Mutation Test
    over1year
    A novel concomitant NRAS and BRAF mutation in metastatic colorectal cancer (ESMO-GI 2023)
    The patient was given folforinox + avastin during 3 months, then Avastin+Xeloda as maintenance treatment. The question is: "Are RAS and BRAF mutations really exclusive to each other"? It seems difficult to answer: even if it's a rare event, it is important to search for BRAF mutations even if RAS is mutatedin specific patients.
    Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF V600E • KRAS mutation • BRAF mutation • NRAS mutation • BRAF V600 • KRAS wild-type • RAS mutation • RAS wild-type • NRAS G12 • NRAS G12C
    |
    Idylla™ KRAS Mutation Test • Idylla™ NRAS-BRAF Mutation Test
    |
    Avastin (bevacizumab) • capecitabine
    2years
    Biocartis announces nine Idylla™ studies to be published at upcoming AMP 2022 annual meeting (Biocartis Press Release)
    "Biocartis Group NV...announces the publication of nine performance study abstracts of its fully automated molecular diagnostics Idylla™ platform and assays at the annual meeting of the ‘Association for Molecular Pathology’ (AMP), a leading molecular diagnostics conference, taking place between 1-5 November in Phoenix, Arizona (US). The studies were performed by a variety of US laboratories and research institutes."
    Clinical data
    |
    Idylla™ GeneFusion Assay • Idylla™ EGFR Mutation Test • Idylla™ MSI Test • Idylla™ NRAS-BRAF Mutation Test
    over2years
    Performance of Idylla RAS-BRAF mutation test for formalin-fixed paraffin-embedded tissues of colorectal cancer. (PubMed, Int J Clin Oncol)
    "This result demonstrates a high concordance between the Idylla KRAS and NRAS-BRAF Mutation Tests and an existing IVD kit. In this manner, the Idylla mutation tests were validated for the detection of clinically significant KRAS, NRAS, and BRAF mutations in FFPE samples from colorectal cancer patients."
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF V600E • KRAS mutation • BRAF mutation • NRAS mutation • BRAF V600 • KIT mutation • RAS mutation
    |
    Idylla™ KRAS Mutation Test • Idylla™ NRAS-BRAF Mutation Test
    3years
    [VIRTUAL] Validation of a Rapid PCR-Based Assay for BRAF V600 Status for Prognostication and Therapeutic Selection in Colorectal Cancer Patients (AMP 2021)
    Our results demonstrate that the Idylla BRAF Mutation Assay produces accurate, precise results in less than 3 hours, with faster TAT compared to NGS. Single-use cartridges eliminate the need for manual sample preprocessing and the risk of PCR contamination. In addition, this sensitive assay correctly identifies BRAF V600 alterations in samples with necrosis and low tumor cell content.
    Clinical
    |
    BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF V600E • NRAS mutation • BRAF V600 • BRAF V600K • BRAF K601E • BRAF L597Q • BRAF V600R • BRAF K601 • BRAF L597
    |
    Idylla™ BRAF Mutation Test • Idylla™ NRAS-BRAF Mutation Test • TruSight Tumor 170 Assay